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Sirolimus (SRL) is an antiproliferative agent inhibiting the
mammalian target of rapamycin (mTOR) proposed as a
non-nephrotoxic alternative to calcineurin inhibitors for the
prevention of acute rejection in renal transplantation.
Despite initial encouraging results, enthusiasm faded with
large trials showing an increased risk of acute rejection with
this molecule that did not provide superior graft function
over cyclosporin or tacrolimus. Recent data showed that SRL,
along with an immunosuppressive activity on CD4þ T cells,
exerts a paradoxical stimulatory effect on innate immunity,
which may explain its incomplete control of alloimmune
response. Moreover, SRL therapy is burdened by a
concerning safety profile including high risk of delayed graft
function and onset of proteinuria. This adds to many other
adverse effects, including dyslipidemia, diabetes,
myelosuppression, delayed wound healing, infertility, ovarian
cysts, and mouth ulcers, that further limit the use of this
molecule. Severe cases of interstitial pneumonia have also
been reported with this therapy, raising additional concerns.
Incomplete control of immune response, along with a poor
tolerability, makes SRL far from being the ideal antirejection
drug. Progressive restrictions of SRL indication in renal
transplantation have, however, been paralleled by evidence
showing mTOR abnormalities involved in many pathogenic
conditions, thus opening the avenue to new possible
applications of this molecule.
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Sirolimus (SRL) and its cognate drug RAD001 (everolimus)
are immunosuppressive drugs that act by inhibiting mam-
malian target of rapamycin (mTOR), an essential regulator of
cell cycle able to block lymphocyte proliferation upon
cytokine engagement.1,2 They have been proposed as an
alternative antirejection therapy to calcineurin inhibitors for
renal transplantation, in light of their immunosuppressive
and antiproliferative properties devoid—according to initial
reports—of renal toxicity. Most of the promises of mTOR
inhibitors, however, have not been fulfilled. Indeed, large
trials showed that SRL therapy is associated with an increased
risk of acute rejections and worse graft function as compared
with cyclosporine (CsA) or tacrolimus (Tac).3 Moreover, its
poor tolerability results in treatment withdrawal in up to
50% of patients due to uncontrolled hyperlipidemia, delayed
wound healing, or mouth ulcers.4,5 Additionally, nephrotoxi-
city has been reported with increasing incidence and raised
further concerns on the safety profile of this molecule.6
Recent experimental evidence also revealed that final effect of
mTOR inhibition in vivo is more complex than initially
thought. Indeed, the suppression of CD4þ effector T cells
with SRL therapy is paralleled by a boost of memory CD8þ T
lymphocytes, which on the one hand may account for the
poor antirejection activity of this drug and on the other one
provides an explanation for the frequently reported signs of
immune system activation, such as interstitial pulmonary
disease and chronic disease anemia.7
Therefore, limited immunosuppressive activity, along with
a concerning safety profile, strongly limits the use of this
molecule in the transplant arena. Despite these limitations,
however, it can be estimated that approximately 5–15,000
patients in the United States and 4–12,000 in Europe,
accounting for 5–15% of the overall population of recipients
of a kidney transplant over the past 10 years, are exposed to
maintenance therapy with SRL-based immunosuppressive
regimens.8–10
EARLY PROMISES FROM mTOR INHIBITORS HAVE NOT BEEN
FULFILLED
Initial trials found that SRL had a superior antirejection effect
over placebo11 or azathioprine12 in renal transplant patients
receiving steroids and full-dose CsA. This, along with
the expected renal safety of SRL, prompted face-to-face
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comparisons between this molecule and CsA. When added to
steroids and azathioprine immunosuppression, the two drugs
were associated with a similar rejection rate that was close to
40%.13 However, when the two drugs were added to a steroid-
and mycophenolate mofetil-based immunosuppressive regi-
men, the rejection rate was remarkably lower (20%) in patients
allocated to CsA than in those on SRL (30%). Difference in the
antirejection potency between mTOR and calcineurin inhibi-
tors became clearer when induction therapy with anti-CD25
antibody was added to the immunosuppressive armamentar-
ium. The largest prospective, randomized, controlled trial in
renal transplant recipients, the Efficacy Limiting Toxicity
Elimination-Symphony Study, showed that among renal
transplant recipients induced with daclizumab and maintained
on chronic immunosuppression with mycophenolate mofetil
and steroids, those randomized to SRL had the lowest
glomerular filtration rate and highest rate of acute rejections
at 1 year compared with those on Tac or CsA. Notably, among
subjects on calcineurin inhibitor therapy those on Tac appeared
to have the best outcomes (Table 1).3
These clinical findings are in line with in vitro evidence that
SRL has a lower immunosuppressive activity as compared with
calcineurin inhibitors on CD8þ memory T cells.14 Impor-
tantly, conversion from CsA to SRL is associated with an
expansion of memory T cells in renal transplant patients with
Kaposi sarcoma.15 This is likely associated with an anticancer
effect, but increases the risk of acute rejection.
Along the same lines, results from basic immunological
research recently showed that, in contrast with what initially
expected, the CD8þ response to various viral stimuli was
enhanced, rather than suppressed, by SRL therapy in mice
and in non-human primates.7 Notably, SRL titrated to blood
levels of 5–20 ng/ml resulted into an expansion of memory
CD8þ T cells and SRL-treated lymphocytes exhibited
improved functional qualities, such as optimized recall
responses and increased protective properties against viral
infections.7,16 During the expansion phase, SRL increased the
number of memory precursors, and during the contraction
phase (effector to memory transition) accelerated the
memory T-cell differentiation program. Conversely, T-
memory cell response was blunted when higher doses
targeting blood levels of 40–100 ng/ml were administered.7
Considering that in renal transplant patients SRL target levels
normally range from 5 to 15 ng/ml,17 the data by Araki et al.7
suggest that in clinical practice SRL therapy is expected to
enhance rather than reduce the response of T-memory cells.
Higher doses targeting levels associated with T-memory cell
inhibition cannot be reached in this setting due to the excess
risk of serious adverse events.18 Moreover, if administered 8
days or later after infection in non-human primates, SRL
therapy enhanced memory T-cell function and recalled ability
independent of achieved serum levels.7 Thus, in clinical
transplantation, SRL therapy is not expected to have specific
tolerogenic effects, and the possibility of a reduced antirejec-
tion efficacy mediated by memory T-cell activation should be
taken into consideration.
Moreover, mTOR has been found to promote proin-
flammatory cytokine production by monocytes, macro-
phages, and peripheral dendritic cells following contact
with Gram-negative and Gram-positive stimuli. Hence,
inhibition of mTOR in these cells results in their immune
activation, as confirmed by the upregulation of interleukin-
12, interleukin-23, and the tumor necrosis factor in vitro.
This may explain why introduction of SRL has been
associated with an increased frequency of unexplained
interstitial pneumonitis in organ transplant patients. Intrigu-
ingly, another indirect sign of a proinflammatory effect of
SRL is the high incidence of anemia with this drug. Indeed,
Table 1 |Main randomized clinical trials of SRL versus CsA in renal transplant patients on immunosuppressive therapy with
steroids plus MMF or AZA
Study
Immunosuppressants
in addition to steroids
Study
drugs
Patients
(no.)
Follow-up
(months)
DGF
(%)
Acute
rejection (%)
Graft
survival (%)
Estimated GFRa
(ml/min)
Study drug
withdrawal (%)
Durrbach et al.66 RATG, MMF SRL 33 6 45.4 12.1 87.5 44.7 48.5**
CsA 36 30.6 8.3 97 41.9 16.7
Ekberg et al.3 Daclizumab, MMF SRL 399 12 21.1** 40.2** 91.7** 56.7** 6.8
CsA 399 32.4 27.2 94.3 59 5.1
Bu¨chler et al.28 RATG, MMF SRL 71 12 18.6 14.3 90 60 28.2
CsA 74 12.3 8.6 93 57 14.9
Pescovitz et al.67 Daclizumab, MMF SRL 30 6 23.3 40.0 100 82.7 NA
CsA 15 13.3 13.3 100 77.8
Flechner et al.68 Basiliximab, MMF SRL 31 60 NA 12.9 96.4* 66.7** NA
CsA 30 23.3 76.7 50.7
Kreis et al.69 MMF SRL 40 12 25 27.5 92.5 NA 43
CsA 38 24 18.4 89.5 26
Groth et al.13 AZA SRL 41 12 NA 41 98 69.5 58.5
CsA 42 38 90 58.7 45.2
Weighted average SRL 645 13.7 22.6 33.9 92.4 51.0 17.9
CsA 634 28.6 23.6 93.0 58.0 11.2
Abbreviations: AZA, azathioprine; CsA, cyclosporine; DGF, delayed graft function; GFR, glomerular filtration rate; MMF, mycophenolate mofetil; NA, not available; RATG, rabbit
anti-human thymoglobulin; SRL, sirolimus.
aMean values at last available follow-up visit. *Po0.05, **Po0.001 vs CsA. Average has been weighted by sample size.
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hemoglobin reduction is paralleled by increased expression of
proinflammatory cytokines, such as interleukin-6 and tumor
necrosis factor-a and defective IL10-dependent inflammatory
autoregulation.19
The aforementioned clinical and experimental results concur
to demonstrate that immune response during mTOR inhibition
is mediated by a suppression of effector CD4þ T cells, which is
however counterbalanced by an activation of the innate
immune response. This eventually results into a poor control
of alloreactivity, which leads to an increased risk of acute
rejection when SRL is used as immunosuppressive agent.20,21
In this context, initial enthusiasm on a stimulatory effect
of SRL on regulatory T cells waned in more recent years.
Indeed, although these cells may control alloreactive response
and promote increased allograft survival in rodent models of
transplantation,22 a randomized controlled study found that
the enhanced number of circulating regulatory T cells
observed in renal transplant recipients allocated to SRL
therapy compared with those on CsA was not associated with
any protective effect against renal allograft injury (Figure 1).23
IS SRL LESS NEPHROTOXIC THAN CsA?
Early studies in animals fuelled enthusiasm on mTOR
inhibitors as antirejection drugs devoid of irritating
nephrotoxic effects of calcineurin inhibitors.23 An initial
small trial found that renal transplant patients on SRL
therapy had significantly lower serum creatinine than
controls on CsA.13 However, this finding was challenged by
data from a subsequent randomized, controlled study in 719
renal transplant patients showing that, on the top of CsA and
steroid immunosuppression, SRL, compared with azathiopr-
ine, was associated with a lower graft function at 12 months
after transplant, despite reduced incidence of acute rejec-
tions.12 This was initially interpreted as the result of a
poorly understood interaction between SRL and CsA that
intensified the nephrotoxic effect of CsA. More recently,
however, evidence came out of a specific nephrotoxic effect
of SRL.
The Sirolimus Renal Conversion Trial found that, among
87 renal transplant patients with a baseline glomerular
filtration rate higher than 40 ml/min, conversion to SRL
approximately 3 years after transplantation was associated
with increased proteinuria and no glomerular filtration rate
improvement, compared with maintenance of calcineurin
inhibitor therapy.24 Even more concerning was that the Drug
Safety Monitoring Board halted the entry of patients with
glomerular filtration rate between 20 and 40 when the
primary safety end point of acute rejection, graft loss, or
death was reached by 8 of 48 patients after SRL conversion
and none of the 25 in the calcineurin inhibitor continuation
arm. These findings were in apparent contrast with those of
the Rapamune Maintenance Regimen study showing that in
525 renal transplant recipients on SRL and steroids main-
tenance therapy, complete CsA withdrawal 3 months after
transplantation was associated with improved allograft
survival as compared with calcineurin inhibitor continuation.
These findings, however, were biased by the fact that about
one-fifth of patients initially enrolled in the study were not
considered in the analyses because of primary non-function,
patient death, or renal vascular thrombosis within 3 months
since transplantation. In this group, patient and graft survival
at 1 year were 82 and 55%, respectively. Moreover, at 4 years
after transplant, roughly a half of the included patients
withdrew the study,5 a drop out rate remarkably higher than
that observed in trials of CsA- or Tac-based immunosup-
pressive regimens.25 Thus, despite the possibility to use SRL
as alternative to CsA is intriguing, available data raise
concern about the risk/benefit profile of this approach.
Consistently, the Early Conversion from Cyclosporine to
Sirolimus After Renal Transplantation study24 showed that
conversion from CsA to SRL at 3 months after transplant was
associated with fast improvement of renal function compared
with continued CsA therapy, but was burdened by a
numerically higher incidence of acute rejections, and more
frequent adverse effects, such as mouth ulcers, diarrhea, acne,
and high triglyceride levels. Notably, as elegantly highlighted
by Servais et al.,26 graft function improvement reflected
changes in glomerular hemodynamics after removal of the
vasoconstrictory effects of CsA,27 but this did not translate
into any kidney structural amelioration.
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Figure 1 | Impact of SRL and CsA therapy on regulatory T cells
and kidney graft outcomes. Time course of circulating
CD4þCD25þ regulatory T cells (a) and rate of measured
glomerular filtration rate (GFR) decline from month 6 to month 30
after renal transplantation (b) in two cohorts of patients
randomized to sirolimus (SRL) or cyclosporine (CsA) therapy in
combination with alemtuzumab induction and mycophenolate
mofetil maintenance immunosuppression. (c, d) Show two
representative photomicrographs of per-protocol renal biopsies
at 2 years after transplant in patients on SRL (c) or CsA (d) therapy.
All samples from SRL patients showed mild-to-moderate tubular
atrophy, interstitial fibrosis with focal interstitial inflammation,
and arteriosclerosis. *Po0.05 vs baseline, yPo0.05 vs SRL at the
same time point. Adapted from Ruggenenti et al.23
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The disappointing effects of SRL therapy on renal graft
outcomes have been initially explained by the poor
immunosuppressive effect of this drug, but they also raised
concerns on a direct nephrotoxic effect of mTOR inhibitors.
This possibility was consistent with evidence that in the
Efficacy Limiting Toxicity Elimination-Symphony Study
5.3% of patients on SRL therapy developed proteinuria
compared with 2.0% of those on CsA.3 Along the same line,
in the Sirolimus versus CsA in Kidney Recipients Receiving
Thymoglobulin trial,28 38.8% of patients on SRL developed
clinical proteinuria compared with 5.6% of those on CsA
(Po0.001). Possible mechanisms underlying the harmful
renal effects of SRL were clarified by studies showing that
prolonged exposure of podocytes to mTOR inhibitor
decreased the expression level of the slit-diaphragm proteins
nephrin and the cytoskeletal adaptor protein Nck. SRL also
reduced cell adhesion and cell motility, which was accom-
panied by an enhanced formation of dot-like actin-rich
structures.29 Consistently, in animal models of kidney
disease, such as puromycin aminonucleoside toxicity30 and
protein overload,31 SRL prevented podocyte regeneration and
aggravated renal injury. These experimental data support a
direct toxic effect of SRL on podocyte function and structure
that may explain why proteinuria levels increase when renal
transplant patients are shifted from CsA to SRL.32 Moreover,
detrimental effect of SRL on podocyte survival might
predispose to de novo focal segmental glomerulosclerosis
lesions reported in renal transplant patients receiving high
doses of SRL.33 mTOR blockade may also promote apoptosis
of tubular epithelial cells and impair their regeneration,
which has been associated with tubular dysfunction34 and
delayed recovery of renal function in some patients after
transplant.35
On the other hand, data showing that SRL reduced
tubulointerstitial inflammation, interstitial fibrosis, and
compensatory renal hypertrophy in the accelerated experi-
mental model of membranous nephropathy36 were not
eventually confirmed in humans. Indeed, SRL failed to
reduce urinary proteins in nine patients with idiopathic
membranous nephropathy, and in the majority of them
treatment had to be prematurely withdrawn because of severe
adverse events, including worsening proteinuria, acute kidney
failure, or infections.37
Thus, experimental and clinical data converge to indicate
that SRL has inherent nephrotoxicity that, however, appears
to differ from patient to patient. Different susceptibility to
SRL toxicity may rely on patients’ genetic background,
preexisting renal damage, and drug levels.33
REASONS FOR FURTHER CONCERN
In addition to poor immunosuppressive potency and renal
toxicity, there are additional drawbacks from SRL therapy,
such as dyslipidemia, diabetes, myelosuppression, mouth
ulcers, and retarded wound healing, infertility, that further
strongly limit SRL prescription (Table 2). Of even more
concern are the cases of life-threatening interstitial pneumo-
nitis reported in patients receiving SRL. This poor safety
profile further limits the room for mTOR inhibitor use in
organ transplantation.
Dyslipidemia
SRL therapy is associated with an increased incidence of
hypercholesterolemia largely mediated by the reduced frac-
tional catabolic rate of very low-density lipoprotein asso-
ciated with mTOR inhibition.38 Finding that approximately
60% of patients receiving mTOR inhibitors in clinical trials
Table 2 | Percentages of patients with major side effects other than proteinuria reported in randomized clinical trials of SRL vs
CsA in renal transplant patients on immunosuppressive therapy with steroids plus MMF or AZA
Study
Study
drugs
New-onset
Diabetes Hypertension Lymphocele
Delayed
wound
healing Anemia Infections Cancer Hypertriglyceridemia
Durrbach et al.66 SRL NA No difference 24.2* 9.1 No difference NA 3.0 NA
CsA 2.0 2.8 2.8
Ekberg et al.3 SRL 7.8 11.8 15.8 16.6 25.0 20.3 2.1 5.0
CsA 4.7 11.5 6.8 11.0 17.4 22.8 0.7 2.9
Bu¨chler et al.28 SRL 9 NA 8 NA 11.8 6*a NA No difference
CsA 3 4 6.4 23
Pescovitz et al.67 SRL 13.3 36.7 NA 20.0 53.3 17 NA 14
CsA 20.0 53.3 0 6.7 7 6
Flechner et al.68 SRL NA No difference 19.4 6.5 NA 45.2 9.7 NA
CsA 13.3 0 53.3 20
Kreis et al.69 SRL 15 40 NA NA 43 5*a 0 73
CsA 16 47 29 21 0 50
Groth et al.13 SRL 20 17 NA NA 37 14a 0 51**
CsA 7 33 24 12 5 12
Weighted average SRL 8.6 12.6 12.8 12.0 24.3 17.4 1.9 11.5
CsA 5.2 13.5 5.5 7.1 15.2 21.8 1.9 5.8
Abbreviations: AZA, azathioprine; CsA, cyclosporine; MMF, mycophenolate mofetil; NA, not available; SRL, sirolimus.
Numbers are percentages or mean values (±s.d.) at last available follow-up visit (g per 24 h).
aCytomegalovirus infection. *Po0.05, **Po0.001 vs CsA. Average has been weighted by sample size.
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required lipid-lowering therapy, which is roughly twice the
number of those receiving lipid-lowering therapy in com-
parator groups,39,40 raises further concerns about the safety
profile and cost-effectiveness of SRL therapy in the transplant
population. Although the long-term consequences of mTOR
inhibitor-induced dyslipidemia in kidney transplant recipi-
ents are unknown, it is reasonable to expect that subjects on
SRL are at increased cardiovascular risk and in most cases
might need concomitant treatment with statins or other
lipid-lowering medications.
Diabetes
Another concerning metabolic effect of mTOR inhibition is
the increased risk of post-transplant diabetes. In an analysis
of more than 20,000 kidney transplant recipients from the US
Renal Data System database, Johnston et al.41 found that
SRL-treated patients had a 25% increased risk of new-onset
diabetes as compared with those receiving other immuosup-
pressive drugs.
Impaired insulin receptor substrate signaling could
explain SRL-induced new-onset diabetes.42 Other mechan-
isms include ectopic triglyceride deposition with SRL leading
to insulin resistance,43 impairment of insulin-mediated
suppression of hepatic glucose production,44 or a direct
toxic effect on pancreatic b-cells.45
Myelosuppression
The myelosuppressive effect of SRL is the direct consequence
of the antiproliferative activity of this compound and is
exacerbated by mycophenolate mofetil co-medication.46 This
frequently results in thrombocytopenia and leucopenia.
Anemia is a less frequent complication of SRL therapy
and, as observed in the anemia of chronic renal insufficiency,
is often associated with low levels of serum iron, high
ferritin concentrations, and refractoriness to erythropoietin
treatment. These changes are believed to reflect a status of
chronic inflammation that in patients on SRL therapy
might be sustained by a stimulatory effect on innate
immunity.20,47
Mouth ulcers
Although not serious, this is the most frequent cause of SRL
discontinuation,48 in particular in patients on concomitant
mycophenolate mofetil therapy.49 The development of mouth
ulcers is dose-related: they usually appear after the loading
dose and often improve after a dose reduction.50 Of note,
topic application of clobetasol, a high-potency topical
steroid, promote a prompt resolution of the mouth ulcers
without the need of empiric SRL dose changes, which may
expose to an increased risk of acute rejection.50
Impaired wound healing
Initial reports on SRL use showed an impaired wound
healing in patients treated with SRL, probably as a
consequence of its antiproliferative activity. Subsequent
analyses suggested that this phenomenon was particularly
relevant in obese patients and accentuated by the concomi-
tant use of steroids.51 However, a systematic program of
wound care in kidney transplant recipients given SRL has
been shown to reduce wound healing complications to the
same rates reported with other antirejection agents. Thus, a
special attention to wound care is needed in transplant
patients on SRL therapy.52
Infertility
Different reports showed that SRL is associated with altered
sex hormone levels and impaired sperm quality.53 Renal
transplant patients on chronic SRL therapy have significantly
reduced total sperm count and a decreased proportion of
motile spermatozoa compared with patients who did not
receive SRL. Of even higher concern, the fathered pregnancy
rate among patients on SRL was 20-fold lower than the one
observed in patients free of SRL. In only a half of patients
who interrupted SRL there was a significant improvement in
sperm parameters.53 This is a frequently underestimated
toxicity of SRL that however should be taken into serious
consideration.
Ovarian toxicity has also been reported in patients
receiving SRL, presenting with a high prevalence of ovarian
cysts of benign nature.54,55 This suggests that evaluation of
female patients on SRL therapy should include menstrual
history and pelvic ultrasound, to assess the presence and
monitor the progression of such alterations.
Pulmonary disease
SRL-induced pulmonary toxicity is a rare but serious entity
that must be considered in the differential diagnosis of a
transplant patient presenting with respiratory compromise.49
In most cases, patients present with a constellation of
symptoms and signs consisting of fever, dyspnea, fatigue, dry
or productive cough, and occasionally hemoptysis. The
outcome of patients with SRL-associated pulmonary disease
varies and may be fatal in around 5% of cases. However,
most patients resolved their clinical and radiographic
findings with discontinuation or dose-reduction of the
drug. High-dose intravenous steroids have been shown to
accelerate recovery.56
The pathophysiology of SRL-associated pulmonary toxi-
city is largely unknown. It has been suggested that SRL may
promote exposure of cryptic pulmonary antigens, resulting in
lymphocytic alveolitis and interstitial pneumonitis.57 Alter-
natively, a direct drug toxicity effect may be responsible for
the syndrome of alveolar hemorrhage without lymphocytic
alveolitis.58 SRL-induced activation of innate immunity
could represent an additional mechanism.20
CONCLUSIONS AND PERSPECTIVES
mTOR inhibitors have been introduced into the clinic as a
potential non-nephrotoxic alternative to calcineurin inhibi-
tors for organ transplantation, but their limited immuno-
suppressive effect, along with poor safety profile, dramatically
limited their use in this clinical setting. In renal transplant
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patients, de novo therapy with SRL has been associated with
increased incidence of delayed graft function and acute
rejections, along with reduced renal graft function compared
with calcineurin inhibitor-based immunosuppressive regi-
mens. This, along with the evidence of a direct nephrotoxic
effect, made of SRL a poorly attracting alternative to CsA or
Tac. Metabolic complications, together with other serious
adverse effects, further limited its use in the transplant
arena.59
On the other hand, uncontrolled activation of mTOR
pathways has a central role in the development of different
tumors, and mTOR inhibition has been associated with
antitumor effects.60 On the basis of this evidence, temsir-
olimus has been recently approved by European Medicine
Agency and Food and Drug Administration for treatment of
advanced renal cell carcinoma.61 As SRL has been also
associated with a reduced incidence of skin and solid organ
cancer compared with calcineurin inhibitors in transplant
patients, conversion to SRL appears to be a reasonable
approach in those patients who develop a malignancy after
kidney transplantation.
Recent findings that SRL promotes expansion of memory
CD8þ T cells might open the perspective of a new indication
for mTOR inhibitors to stimulate the immune response to
vaccines. Boosting memory T-cell response by mTOR
inhibitor therapy might help inducing long-lasting protective
immune memory against bacterial or viral pathogens strong
enough to prevent their replication,62 especially in transplant
recipients and other immunosuppressed patients with
autoimmune disorders. Consistently, SRL therapy seems to
be associated with reduced incidence of BK virus infection
compared with calcineurin inhibitors. Thus, conversion to
mTOR inhibitors may represent a valuable option in those
cases with persistent infection resistant to antiviral ther-
apy.63,64 Even more intriguing is the evidence that SRL can
directly inhibit human immunodeficiency virus replication.65
Altogether, the above data can be taken to suggest that no
renal transplant patient should receive de novo SRL therapy
and that the use of SRL should be restricted to very selected
patients, such as those with post-transplant malignancies or,
probably, treatment-resistant viral infection. In such patients,
the risk/benefit profile of SRL therapy should be carefully
considered on a case-by-case basis. On the other hand, in
subjects with stable kidney function and no evidence of
treatment-related side effects, there is no reason to stop
mTOR inhibitor therapy.
Further research should aim at exploring new specific
clinical indications for the immunostimulatory properties of
the drug.
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